Compare PACK & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PACK | AURA |
|---|---|---|
| Founded | 1972 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.6M | 713.4M |
| IPO Year | 2017 | 2021 |
| Metric | PACK | AURA |
|---|---|---|
| Price | $6.89 | $6.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $6.50 | ★ $20.00 |
| AVG Volume (30 Days) | 574.7K | ★ 717.0K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $395,000,000.00 | N/A |
| Revenue This Year | $9.29 | N/A |
| Revenue Next Year | $8.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.08 | N/A |
| 52 Week Low | $3.22 | $4.73 |
| 52 Week High | $7.81 | $9.54 |
| Indicator | PACK | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 52.25 | 47.86 |
| Support Level | $6.59 | $6.34 |
| Resistance Level | $7.16 | $7.04 |
| Average True Range (ATR) | 0.35 | 0.55 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 46.85 | 23.13 |
Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.